Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA.
Moore KN, et al. Among authors: banerjee s.
Gynecol Oncol. 2024 Oct 25;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Online ahead of print.
Gynecol Oncol. 2024.
PMID: 39461270